60 Degrees Pharmaceuticals
SXTP60 Degrees Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of small molecule therapies for infectious diseases.
Table of contents
Earnings
Next report
Aug 12, 2026 (In 2 weeks)Competitors
By market cap
By revenue growth
Profile
60 Degrees Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of small molecule therapies for infectious diseases. The company leverages cutting-edge biological science and research partnerships to reposition molecules with established safety profiles for new therapeutic indications. Its core value proposition lies in an inexpensive product development model that targets unmet medical needs in vector-borne, fungal, and viral diseases.
A specialty player utilizing a virtual management model to achieve clinical milestones at a significantly lower cost than traditional biotechnology firms.
Questions, answered.
- What is 60 Degrees Pharmaceuticals's market cap?
- 60 Degrees Pharmaceuticals (SXTP) has a market capitalization of $4.2M and trades on NASDAQ.
- Who are 60 Degrees Pharmaceuticals's competitors?
- 60 Degrees Pharmaceuticals's key competitors include Cumberland Pharmaceuticals Inc, Scienture Holdings, Inc. Common Stock, Zevra Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does 60 Degrees Pharmaceuticals partner with?
- 60 Degrees Pharmaceuticals's notable partners include U.S. Army, National University of Singapore, Tufts Medical Center, and others.
- What subsidiaries does 60 Degrees Pharmaceuticals have?
- 60 Degrees Pharmaceuticals's subsidiaries include 60P Australia Pty Ltd.
- Where is 60 Degrees Pharmaceuticals headquartered?
- 60 Degrees Pharmaceuticals is headquartered in United States of America and employs approximately 2 people. It has been publicly traded since 2023.